SCHEMBL16178755

SCHEMBL16178755

COc1ncc(NC(=O)N2CCNC(C)C2)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 8/20 0.40
▸ MAPT P10636 1/20 0.39
▸ CCR3 P51677 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ CCR2 P41597 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ BRPF1 P55201 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16178714 0.82 NTRK1 (0.39) NTRK1CCR2KCNH2
SCHEMBL6716470 0.80 MAPT (0.65) MAPTALDH1A1GAASMN1; SMN2
SCHEMBL16178778 0.79 CCR2 (0.45) NTRK1CCR2CCR5KCNH2
SCHEMBL16178743 0.78 REN (0.38) NTRK1
SCHEMBL16178483 0.78 HTT (0.65) MAPTCCR3POLBHTTALDH1A1
SCHEMBL16178505 0.78 RAB9A (0.57) MAPTPOLBALDH1A1GAAGFER
SCHEMBL7890248 0.76 POLB (0.66) MAPTPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL16178773 0.75 PI4KB (0.48) NTRK1
SCHEMBL16178733 0.75 PKM (0.64) MAPTPOLBALDH1A1GAAMAPK1
SCHEMBL16178784 0.74 HRH4 (0.38) NTRK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 NTRK1 3223/4885MAPT 2357/4885CCR3 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback